Universita' Cattolica del Sacro Cuore Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Milan Italy (1921)

Organization Overview

First Clinical Trial
2006
NCT00418574
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fondazione Policlinico A. Gemelli IRCCS | Fondazione Policlinico Agostino Gemelli IRCCS | Fondazione Policlinico Gemelli IRCCS | Fondazione Policlinico Universitario A. Gemelli, IRCCS | Fondazione Policlinico Universitario A. Gemelli IRCCS; Università Cattolica del Sacro Cuore | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore | Unit for Hematology and BMT, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy | University Cattolica del Sacro Cuore Roma Italy | Universtita' Cattolica del Sacro Cuore | Universtita' Cattolica del Sacro Cuore, Dipartimento di Oncologia - Roma, Italy

Active Ingredients

Drugs in Phase 4 Trials (8)

acetylsalicylic acid (aspirin) (1 trial)

clavulanate (Augmentin) (1 trial)

clopidogrel (plavix) (1 trial)

colistin (1 trial)

diltiazem (cardizem) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 3 Trials (16)

Abagovomab (1 trial)

bevacizumab (avastin) (2 trials)

COVID-19 convalescent plasma (1 trial)

dolutegravir (tivicay) (1 trial)

dostarlimab (1 trial)

doxorubicin (Doxil) (2 trials)

exemestane (aromasin) (1 trial)

gemcitabine (gemzar) (2 trials)

lamivudine (epivir) (1 trial)

letrozole (femara) (1 trial)

niraparib (zejula) (1 trial)

paclitaxel (taxol) (7 trials)

pamrevlumab (1 trial)

sugammadex (bridion) (1 trial)

topotecan (hycamtin) (2 trials)

umbilical cord blood platelet-rich plasma (1 trial)

Drugs in Phase 2 Trials (18)

allogeneic bone marrow (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

avelumab (bavencio) (1 trial)

axitinib (inlyta) (1 trial)

carboplatin (paraplatin) (3 trials)

cisplatin (platinol) (1 trial)

cord blood erythrocytes (1 trial)

fentanyl (Innovar) (1 trial)

flurbiprofen (ansaid) (1 trial)

human fecal microbiota (Reybota) (2 trials)

nivolumab (opdivo) (1 trial)

olaparib (lynparza) (1 trial)

pembrolizumab (keytruda) (3 trials)

poractant alfa (curosurf) (1 trial)

red blood cells (1 trial)

remifentanil (ultiva) (1 trial)

rucaparib (rubraca) (1 trial)

sargramostim (leukine) (1 trial)

Drugs in Phase 1 Trials (1)

tbx-2400 (1 trial)

Drugs in Other Trials (18)

arginine (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

curcumin (1 trial)

epinephrine (levophed) (1 trial)

indocyanine green (ic-green) (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus delbrueckii (1 trial)

lactobacillus plantarum (1 trial)

macrogol (1 trial)

mesalamine (rowasa) (1 trial)

morphine (1 trial)

oxygen (1 trial)

ropivacaine (naropin) (2 trials)

streptococcus salivarius (1 trial)

vsl #3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anterior Wall Myocardial Infarction (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Disease Progression (Phase 3)

Fallopian Tube Neoplasms (Phase 2)

Infarction (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myocardial Infarction (Phase 2)

Ovarian Neoplasms (Phase 3)

Preleukemia (Phase 2)

Pulmonary Valve Insufficiency (Phase 2)

Respiratory Insufficiency (Phase 2)

Retinitis (Phase 3)

Retinitis Pigmentosa (Phase 3)

Sinusitis (Phase 4)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial APIs: 61